Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,660 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Aperiodic neural activity is a biomarker for depression severity.
Hacker C, Mocchi MM, Xiao J, Metzger BA, Adkinson JA, Pascuzzi BR, Mathura RC, Oswalt D, Watrous A, Bartoli E, Allawala A, Pirtle V, Fan X, Danstrom I, Shofty B, Banks G, Zhang Y, Armenta-Salas M, Mirpour K, Provenza N, Mathew S, Cohn J, Borton D, Goodman W, Pouratian N, Sheth SA, Bijanki KR. Hacker C, et al. Among authors: mathew s. medRxiv [Preprint]. 2023 Nov 8:2023.11.07.23298040. doi: 10.1101/2023.11.07.23298040. medRxiv. 2023. PMID: 37986996 Free PMC article. Preprint.
Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: results of a double-blind, placebo-controlled trial.
Rickels K, Mathew S, Banov MD, Zimbroff DL, Oshana S, Parsons EC Jr, Donahue SR, Kauffman M, Iyer GR, Reinhard JF Jr. Rickels K, et al. Among authors: mathew s. J Clin Psychopharmacol. 2008 Apr;28(2):235-9. doi: 10.1097/JCP.0b013e31816774de. J Clin Psychopharmacol. 2008. PMID: 18344738 Clinical Trial.
Ketamine for depression clinical issues.
Iqbal SZ, Mathew SJ. Iqbal SZ, et al. Adv Pharmacol. 2020;89:131-162. doi: 10.1016/bs.apha.2020.02.005. Epub 2020 Apr 1. Adv Pharmacol. 2020. PMID: 32616205 Review.
A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating κ-opioid antagonism as a treatment for anhedonia.
Krystal AD, Pizzagalli DA, Smoski M, Mathew SJ, Nurnberger J Jr, Lisanby SH, Iosifescu D, Murrough JW, Yang H, Weiner RD, Calabrese JR, Sanacora G, Hermes G, Keefe RSE, Song A, Goodman W, Szabo ST, Whitton AE, Gao K, Potter WZ. Krystal AD, et al. Among authors: mathew sj. Nat Med. 2020 May;26(5):760-768. doi: 10.1038/s41591-020-0806-7. Epub 2020 Mar 30. Nat Med. 2020. PMID: 32231295 Free PMC article. Clinical Trial.
Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression.
Guo W, Machado-Vieira R, Mathew S, Murrough JW, Charney DS, Grunebaum M, Oquendo MA, Kadriu B, Akula N, Henter I, Yuan P, Merikangas K, Drevets W, Furey M, Mann JJ, McMahon FJ, Zarate CA Jr, Shugart YY. Guo W, et al. Among authors: mathew s. Transl Psychiatry. 2018 Dec 14;8(1):280. doi: 10.1038/s41398-018-0311-7. Transl Psychiatry. 2018. PMID: 30552317 Free PMC article.
Correction to: Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS).
Pizzagalli DA, Smoski M, Ang YS, Whitton AE, Sanacora G, Mathew SJ, Nurnberger J Jr, Lisanby SH, Iosifescu DV, Murrough JW, Yang H, Weiner RD, Calabrese JR, Goodman W, Potter WZ, Krystal AD. Pizzagalli DA, et al. Neuropsychopharmacology. 2021 Nov;46(12):2224. doi: 10.1038/s41386-021-01145-9. Neuropsychopharmacology. 2021. PMID: 34389811 Free PMC article. No abstract available.
1,660 results